Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?

Area of Science:

• Dermatology
• Immunology
• Autoimmune Diseases

Background:

• Pemphigus is a rare autoimmune blistering disorder affecting skin and mucous membranes.
• Pathogenic immunoglobulin G (IgG) autoantibodies target desmoglein-1 and desmoglein-3, compromising desmosome integrity.
• Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the main forms, with PV being most common and potentially life-threatening due to barrier dysfunction.

Purpose of the Study:

• To provide a comprehensive overview of the current treatment landscape for pemphigus.
• To highlight established therapeutic approaches for pemphigus management.
• To discuss emerging therapeutic strategies for pemphigus.

Main Methods:

• This review synthesizes current literature on pemphigus treatments.
• It examines the role of autoantibodies in pemphigus pathogenesis.
• The review assesses the efficacy of existing and novel therapies, including rituximab.

Main Results:

• Rituximab, an anti-CD20 monoclonal antibody, has significantly improved treatment outcomes in pemphigus.
• Established treatments focus on immunosuppression to reduce autoantibody production.
• Emerging therapies aim for more targeted approaches to pemphigus management.

Conclusions:

• Pemphigus treatment has advanced significantly, particularly with the advent of biologics like rituximab.
• Effective management requires understanding the autoimmune basis and targeting pathogenic autoantibodies.
• Continued research into novel therapeutics promises further improvements in pemphigus care.